Establishment of a consensus definition for mesenchymal stromal cells (MSC) and reporting guidelines for clinical trials of MSC therapy: a modified Delphi study protocol

被引:11
作者
Renesme, Laurent [1 ]
Cobey, Kelly D. [2 ,3 ]
Le, Maxime [4 ]
Lalu, Manoj M. [3 ,5 ]
Thebaud, Bernard [1 ,6 ,7 ]
机构
[1] Ottawa Hosp Res Inst, Sinclair Ctr Regenerat Med, Ottawa, ON, Canada
[2] Ottawa Hosp Res Inst, Ctr Journalol, Clin Epidemiol Program, Ottawa, ON, Canada
[3] Univ Ottawa, Sch Epidemiol & Publ Hlth, Fac Med, Ottawa, ON, Canada
[4] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[5] Univ Ottawa, Dept Anesthesiol & Pain Med, Fac Med, Ottawa, ON, Canada
[6] CHEO Res Inst, Dept Pediat, Neonatol, Ottawa, ON, Canada
[7] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada
关键词
protocols & guidelines; cell biology; therapeutics; CRITERIA;
D O I
10.1136/bmjopen-2021-054740
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Despite being more than two decades of research, mesenchymal stromal cell (MSC) treatments are still struggling to cross the translational gap. Two key issues that likely contribute to these failures are (1) the lack of clear definition for MSC and (2) poor quality of reporting in MSC clinical studies. To address these issues, we propose a modified Delphi study to establish a consensus definition for MSC and reporting guidelines for clinical trials of MSC therapy. Methods and analysis We will conduct a three-round international modified Delphi survey. Findings from a recent scoping review examining how MSCs are defined and reported in preclinical and clinical studies were used to draft the initial survey for round 1 of our Delphi. Participants will include a 'core group' of individuals as well as researchers whose work was captured in our scoping review. The core group will include stakeholders from different research fields including developmental biology, translational science, research methods, regulatory practices, scholarly journal editing and industry. The first two survey rounds will be online, and the final round will take place in person. Each participant will be asked to rate their agreement on potential MSC definition characteristics and reporting items using a Likert scale. After each round, we will analyse the data to determine which items have reached consensus for inclusion/exclusion, and then develop a revised questionnaire for any new items, or items that did not reach consensus. Ethics and dissemination This study received ethical approval from the Ottawa Health Research Network Research Ethics Board. To support the dissemination of our findings, we will use an evidence-based 'integrated knowledge translation' approach to engage knowledge users from the inception of the research. This will allow us to develop a tailored end-of-project knowledge translation plan to support and ensure dissemination and implementation of the Delphi results.
引用
收藏
页数:5
相关论文
共 21 条
[1]   EXPERIMENTAL STUDY OF GROUP OPINION - DELPHI METHOD [J].
DALKEY, N .
FUTURES, 1969, 1 (05) :408-426
[2]   Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies [J].
Diamond, Ivan R. ;
Grant, Robert C. ;
Feldman, Brian M. ;
Pencharz, Paul B. ;
Ling, Simon C. ;
Moore, Aideen M. ;
Wales, Paul W. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2014, 67 (04) :401-409
[3]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[4]  
FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
[5]   Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities [J].
Galipeau, Jacques ;
Sensebe, Luc .
CELL STEM CELL, 2018, 22 (06) :824-833
[6]   Predatory journals: no definition, no defence [J].
Grudniewicz, Agnes ;
Moher, David ;
Cobey, Kelly D. ;
Bryson, Gregory L. ;
Cukier, Samantha ;
Allen, Kristiann ;
Ardern, Clare ;
Balcom, Lesley ;
Barros, Tiago ;
Berger, Monica ;
Ciro, Jairo Buitrago ;
Cugusi, Lucia ;
Donaldson, Michael R. ;
Egger, Matthias ;
Graham, Ian D. ;
Hodgkinson, Matt ;
Khan, Karim M. ;
Mabizela, Mahlubi ;
Manca, Andrea ;
Milzow, Katrin ;
Mouton, Johann ;
Muchenje, Marvelous ;
Olijhoek, Tom ;
Ommaya, Alexander ;
Patwardhan, Bhushan ;
Poff, Deborah ;
Proulx, Laurie ;
Rodger, Marc ;
Severin, Anna ;
Strinzel, Michaela ;
Sylos-Labini, Mauro ;
Tamblyn, Robyn ;
van Niekerk, Marthie ;
Wicherts, Jelte M. ;
Lalu, Manoj M. .
NATURE, 2019, 576 (7786) :210-212
[7]   Defining Integrated Knowledge Translation and Moving Forward: A Response to Recent Commentaries [J].
Kothari, Anita ;
McCutcheon, Chris ;
Graham, Ian D. .
INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2017, 6 (05) :299-+
[8]   Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials [J].
Lalu, Manoj M. ;
McIntyre, Lauralyn ;
Pugliese, Christina ;
Fergusson, Dean ;
Winston, Brent W. ;
Marshall, John C. ;
Granton, John ;
Stewart, Duncan J. .
PLOS ONE, 2012, 7 (10)
[9]  
LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557
[10]   Shattering barriers toward clinically meaningful MSC therapies [J].
Levy, Oren ;
Kuai, Rui ;
Siren, Erika M. J. ;
Bhere, Deepak ;
Milton, Yuka ;
Nissar, Nabeel ;
De Biasio, Michael ;
Heinelt, Martina ;
Reeve, Brock ;
Abdi, Reza ;
Alturki, Meshael ;
Fallatah, Mohanad ;
Almalik, Abdulaziz ;
Alhasan, Ali H. ;
Shah, Khalid ;
Karp, Jeffrey M. .
SCIENCE ADVANCES, 2020, 6 (30)